Liver Neoplasms  >>  Inlyta (axitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
NCT01210495 / 2010-021590-37: Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
224
Japan, US, Europe, RoW
Axitinib (AG-013736), Best Supportive Care, Placebo
Pfizer
Hepatocellular Carcinoma
03/14
12/16
NCT01273662: Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma

Completed
2
45
RoW
AG-013736, Axitinib
National Taiwan University Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
03/16
12/16
NCT01352728: Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
2
50
RoW
Axitinib
Chinese University of Hong Kong
Hepatocellular Carcinoma
06/18
06/18

Download Options